EGFR and non-small cell lung carcinoma: Several studies have detected the coexistence of c-Met dysregulation and EGFR gene mutations in tumor tissues of NSCLC patients, and demonstrated that the PFS of patients with both EGFR mutations and c-Met gene amplification was significantly shorter than in patients with EGFR mutations alone [22, 23].